Brain metabolic dysfunction at the core of Alzheimer's disease

Biochemical Pharmacology

Volumn 88, Issue 4, 2014, Pages 548-559

  De La Monte, Suzanne M ^a,b   Tong, Ming ^a  

^a BROWN UNIVERSITY   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; Ceramides; Insulin resistance; Lifestyle; Metabolic syndrome; Nitrosamines; Non alcoholic fatty liver disease; Obesity; Type 3 diabetes

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMYLOID BETA PROTEIN; CERAMIDE DERIVATIVE; CYANOCOBALAMIN; CYCLIN DEPENDENT KINASE 5; DIETHYLNITROSAMINE; DIMETHYLNITROSAMINE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE TRANSPORTER 4; GLYCOGEN SYNTHASE KINASE 3BETA; INSULIN; PRESENILIN 1; PRESENILIN 2; SOMATOMEDIN C; TAU PROTEIN;

AGING; ALZHEIMER DISEASE; BRAIN FUNCTION; COGNITION; COGNITIVE DEFECT; DNA ADDUCT; DNA DAMAGE; ENDOPLASMIC RETICULUM STRESS; ENVIRONMENTAL FACTOR; GENE EXPRESSION; GLUCOSE METABOLISM; GLUCOSE UTILIZATION; HEREDITY; INSULIN RESISTANCE; LIFESTYLE; LIPID METABOLISM; METABOLIC DISORDER; METABOLIC SYNDROME X; MICROANGIOPATHY; NERVE CELL PLASTICITY; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROFIBRILLARY TANGLE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; OVARY POLYCYSTIC DISEASE; OXIDATIVE STRESS; PHASIC INSULIN DEPENDENT DIABETES MELLITUS; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RETINA MACULA AGE RELATED DEGENERATION; REVIEW;

ADVANCED GLYCATION END-PRODUCTS; ALZHEIMER'S DISEASE; CERAMIDES; INSULIN RESISTANCE; LIFESTYLE; METABOLIC SYNDROME; N-NITROSODIETHYLAMINE; NITROSAMINE; NITROSAMINES; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; REACTIVE NITROGEN SPECIES; STREPTOZOTOCIN; TYPE 3 DIABETES;

ALZHEIMER DISEASE; BRAIN; ENVIRONMENTAL EXPOSURE; HUMANS; INSULIN; INSULIN RESISTANCE; SOMATOMEDINS;

EID: 84897954482     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2013.12.012     Document Type: Review

References (208)

1. M. Zeyda, and T.M. Stulnig Obesity, inflammation, and insulin resistance - a mini-review Gerontology 55 2009 379 386
2. J.F. Kuemmerle Insulin-like growth factors in the gastrointestinal tract and liver Endocrinol Metab Clin North Am 41 2012 409 423 [vii]
3. S.M. de la Monte, and J.R. Wands Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease J Alzheimers Dis 7 2005 45 61 (Pubitemid 40387184)
4. A.J. D'Ercole, and P. Ye Expanding the mind: insulin-like growth factor I and brain development Endocrinology 149 2008 5958 5962
5. S. Freude, K. Schilbach, and M. Schubert The role of IGF-1 receptor and insulin receptor signaling for the pathogenesis of Alzheimer's disease: from model organisms to human disease Curr Alzheimer Res 6 2009 213 223
6. M. Zeger, G. Popken, J. Zhang, S. Xuan, Q.R. Lu, and M.H. Schwab et al. Insulin-like growth factor type 1 receptor signaling in the cells of oligodendrocyte lineage is required for normal in vivo oligodendrocyte development and myelination Glia 55 2007 400 411
7. S.M. de la Monte, L. Longato, M. Tong, S. DeNucci, and J.R. Wands The liver-brain axis of alcohol-mediated neurodegeneration: role of toxic lipids Int J Environ Res Public Health 6 2009 2055 2075
8. S.M. de la Monte, L. Longato, M. Tong, and J.R. Wands Insulin resistance and neurodegeneration: roles of obesity, type 2 diabetes mellitus and non-alcoholic steatohepatitis Curr Opin Investig Drugs 10 2009 1049 1060
9. M.H. Shanik, Y. Xu, J. Skrha, R. Dankner, Y. Zick, and J. Roth Insulin resistance and hyperinsulinemia: is hyperinsulinemia the cart or the horse? Diabetes Care 31 Suppl. 2 2008 S262 S268
10. R. Dankner, A. Chetrit, M.H. Shanik, I. Raz, and J. Roth Basal-state hyperinsulinemia in healthy normoglycemic adults is predictive of type 2 diabetes over a 24-year follow-up: a preliminary report Diabetes Care 32 2009 1464 1466
11. R.G. Garcia, M.Y. Rincon, W.D. Arenas, S.Y. Silva, L.M. Reyes, and S.L. Ruiz et al. Hyperinsulinemia is a predictor of new cardiovascular events in Colombian patients with a first myocardial infarction Int J Cardiol 148 2011 85 90
12. T. Kasai, K. Miyauchi, K. Kajimoto, N. Kubota, T. Dohi, and T. Kurata et al. The adverse prognostic significance of the metabolic syndrome with and without hypertension in patients who underwent complete coronary revascularization J Hypertens 27 2009 1017 1024
13. C. Agnoli, F. Berrino, C.A. Abagnato, P. Muti, S. Panico, and P. Crosignani et al. Metabolic syndrome and postmenopausal breast cancer in the ORDET cohort: a nested case-control study Nutr Metabol Cardiovasc Dis 20 2010 41 48
14. M.H. Faulds, and K. Dahlman-Wright Metabolic diseases and cancer risk Curr Opin Oncol 24 2012 58 61
15. S.V. Colonna, L. Douglas Case, and J.A. Lawrence A retrospective review of the metabolic syndrome in women diagnosed with breast cancer and correlation with estrogen receptor Breast Cancer Res Treat 131 2012 325 331
16. L. Frolich, D. Blum-Degen, H.G. Bernstein, S. Engelsberger, J. Humrich, and S. Laufer et al. Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease J Neural Transm 105 1998 423 438 (Pubitemid 28365027)
17. S. Hoyer Glucose metabolism and insulin receptor signal transduction in Alzheimer disease Eur J Pharmacol 490 2004 115 125 (Pubitemid 38482165)
18. E.J. Rivera, A. Goldin, N. Fulmer, R. Tavares, J.R. Wands, and S.M. de la Monte Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine J Alzheimers Dis 8 2005 247 268
19. E. Steen, B.M. Terry, E.J. Rivera, J.L. Cannon, T.R. Neely, and R. Tavares et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease - is this type 3 diabetes J Alzheimers Dis 7 2005 63 80 (Pubitemid 40387185)
20. S.M. de la Monte Therapeutic targets of brain insulin resistance in sporadic Alzheimer's disease Front Biosci E4 2012 1582 1605
21. S.M. de la Monte, E. Re, L. Longato, and M. Tong Dysfunctional pro-ceramide, ER stress, and insulin/IGF signaling networks with progression of Alzheimer's disease J Alzheimers Dis 30 2012 S217 S229
22. R.J. Caselli, K. Chen, W. Lee, G.E. Alexander, and E.M. Reiman Correlating cerebral hypometabolism with future memory decline in subsequent converters to amnestic pre-mild cognitive impairment Arch Neurol 65 2008 1231 1236
23. L. Mosconi, A. Pupi, and M.J. De Leon Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease Ann N Y Acad Sci 1147 2008 180 195
24. J.B. Langbaum, K. Chen, R.J. Caselli, W. Lee, C. Reschke, and D. Bandy et al. Hypometabolism in Alzheimer-affected brain regions in cognitively healthy Latino individuals carrying the apolipoprotein E epsilon4 allele Arch Neurol 67 2010 462 468
25. S. Hoyer, and R. Nitsch Cerebral excess release of neurotransmitter amino acids subsequent to reduced cerebral glucose metabolism in early-onset dementia of Alzheimer type J Neural Transm 75 1989 227 232 (Pubitemid 19039949)
26. S. Hoyer, R. Nitsch, and K. Oesterreich Predominant abnormality in cerebral glucose utilization in late-onset dementia of the Alzheimer type: a cross-sectional comparison against advanced late-onset and incipient early-onset cases J Neural Transm Park Dis Dement Sect 3 1991 1 14
27. K. Talbot, H.Y. Wang, H. Kazi, L.Y. Han, K.P. Bakshi, and A. Stucky et al. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline J Clin Invest 122 2012 1316 1338
28. N. Lester-Coll, E.J. Rivera, S.J. Soscia, K. Doiron, J.R. Wands, and S.M. de la Monte Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease J Alzheimers Dis 9 2006 13 33
29. M. Weinstock, and S. Shoham Rat models of dementia based on reductions in regional glucose metabolism, cerebral blood flow and cytochrome oxidase activity J Neural Transm 111 2004 347 366 (Pubitemid 38316610)
30. A.D. Bolzan, and M.S. Bianchi Genotoxicity of streptozotocin Mutat Res 512 2002 121 134 (Pubitemid 35441051)
31. M. Koulmanda, A. Qipo, S. Chebrolu, J. O'Neil, H. Auchincloss, and R.N. Smith The effect of low versus high dose of streptozotocin in cynomolgus monkeys (Macaca fascilularis) Am J Transplant 3 2003 267 272 (Pubitemid 36407043)
32. S.M. de la Monte, M. Tong, N. Bowling, and P. Moskal si-RNA inhibition of brain insulin or insulin-like growth factor receptors causes developmental cerebellar abnormalities: relevance to fetal alcohol spectrum disorder Mol Brain 4 2011 13
33. I. Salcedo, D. Tweedie, Y. Li, and N.H. Greig Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders Br J Pharmacol 166 2012 1586 1599
34. J. Piriz, A. Muller, J.L. Trejo, and I. Torres-Aleman IGF-I and the aging mammalian brain Exp Gerontol 46 2011 96 99
35. M.P. Mattson The impact of dietary energy intake on cognitive aging Front Aging Neurosci 2 2010 5
36. M. Schubert, D. Gautam, D. Surjo, K. Ueki, S. Baudler, and D. Schubert et al. Role for neuronal insulin resistance in neurodegenerative diseases Proc Natl Acad Sci U S A 101 2004 3100 3105 (Pubitemid 38327741)
37. C. Duyckaerts, B. Delatour, and M.C. Potier Classification and basic pathology of Alzheimer disease Acta Neuropathol 118 2009 5 36
38. P.E. Fraser, G. Yu, L. Levesque, M. Nishimura, D.S. Yang, and H.T. Mount et al. Presenilin function: connections to Alzheimer's disease and signal transduction Biochem Soc Symp 67 2001 89 100 (Pubitemid 33602677)
39. I. Morales, G. Farias, and R.B. Maccioni Neuroimmunomodulation in the pathogenesis of Alzheimer's disease Neuroimmunomodulation 17 2010 202 204
40. K. Iqbal, F. Liu, and C.X. Gong Alonso Adel C, Grundke-Iqbal I. Mechanisms of tau-induced neurodegeneration Acta Neuropathol 118 2009 53 69
41. R. Bhat, Y. Xue, S. Berg, S. Hellberg, M. Ormo, and Y. Nilsson et al. Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418 J Biol Chem 278 2003 45937 45945 (Pubitemid 37432740)
42. A. Takashima Drug development for tauopathy and Alzheimer's disease Nihon Shinkei Seishin Yakurigaku Zasshi 30 2010 177 180
43. L. Arnaud, N.K. Robakis, and M.E. Figueiredo-Pereira It may take inflammation, phosphorylation and ubiquitination to 'tangle' in Alzheimer's disease Neurodegener Dis 3 2006 313 319 (Pubitemid 46034207)
44. S. Oddo The ubiquitin-proteasome system in Alzheimer's disease J Cell Mol Med 12 2008 363 373 (Pubitemid 351555121)
45. E.M. Mandelkow, K. Stamer, R. Vogel, E. Thies, and E. Mandelkow Clogging of axons by tau, inhibition of axonal traffic and starvation of synapses Neurobiol Aging 24 2003 1079 1085 (Pubitemid 37487885)
46. S.M. de la Monte, G.J. Chen, E. Rivera, and J.R. Wands Neuronal thread protein regulation and interaction with microtubule-associated proteins in SH-Sy5y neuronal cells Cell Mol Life Sci 60 2003 2679 2691 (Pubitemid 38041368)
47. B.W. Doble, and J.R. Woodgett GSK-3: tricks of the trade for a multi-tasking kinase J Cell Sci 116 2003 1175 1186 (Pubitemid 36410657)
48. N.K. Robakis Mechanisms of AD neurodegeneration may be independent of Abeta and its derivatives Neurobiol Aging 32 2011 372 379
49. L. Wu, P. Rosa-Neto, G.Y. Hsiung, A.D. Sadovnick, M. Masellis, and S.E. Black et al. Early-onset familial Alzheimer's disease (EOFAD) Can J Neurol Sci 39 2012 436 445
50. D. Bosco, A. Fava, M. Plastino, T. Montalcini, and A. Pujia Possible implications of insulin resistance and glucose metabolism in Alzheimer's disease pathogenesis J Cell Mol Med 15 2011 1807 1821
51. M.R. Emmerling, K. Spiegel, and M.D. Watson Inhibiting the formation of classical C3-convertase on the Alzheimer's beta-amyloid peptide Immunopharmacology 38 1997 101 109 (Pubitemid 28049970)
52. I. Blasko, M. Stampfer-Kountchev, P. Robatscher, R. Veerhuis, P. Eikelenboom, and B. Grubeck-Loebenstein How chronic inflammation can affect the brain and support the development of Alzheimer's disease in old age: the role of microglia and astrocytes Aging Cell 3 2004 169 176 (Pubitemid 40253499)
53. G.S. Watson, E.R. Peskind, S. Asthana, K. Purganan, C. Wait, and D. Chapman et al. Insulin increases CSF Abeta42 levels in normal older adults Neurology 60 2003 1899 1903 (Pubitemid 36736003)
54. L. Gasparini, W.J. Netzer, P. Greengard, and H. Xu Does insulin dysfunction play a role in Alzheimer's disease Trends Pharmacol Sci 23 2002 288 293 (Pubitemid 34655735)
55. A.F. Schuh, C.M. Rieder, L. Rizzi, M. Chaves, and M. Roriz-Cruz Mechanisms of brain aging regulation by insulin: implications for neurodegeneration in late-onset Alzheimer's disease ISRN Neurol 2011 2011 306905
56. C. Messier, and K. Teutenberg The role of insulin, insulin growth factor, and insulin-degrading enzyme in brain aging and Alzheimer's disease Neural Plast 12 2005 311 328 (Pubitemid 43072007)
57. L. Xie, E. Helmerhorst, K. Taddei, B. Plewright, W. Van Bronswijk, and R. Martins Alzheimer's beta-amyloid peptides compete for insulin binding to the insulin receptor J Neurosci 22 2002 RC221
58. C.J. Phiel, C.A. Wilson, V.M. Lee, and P.S. Klein GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides Nature 423 2003 435 439 (Pubitemid 36626994)
59. P. Eikelenboom, E. van Exel, J.J. Hoozemans, R. Veerhuis, A.J. Rozemuller, and W.A. van Gool Neuroinflammation - an early event in both the history and pathogenesis of Alzheimer's disease Neurodegener Dis 7 2010 38 41
60. I. Blasko, S. Jungwirth, K. Jellinger, G. Kemmler, W. Krampla, and S. Weissgram et al. Effects of medications on plasma amyloid beta (Abeta) 42: longitudinal data from the VITA cohort J Psychiatr Res 42 2008 946 955
61. C.A. Szekely, and P.P. Zandi Non-steroidal anti-inflammatory drugs and Alzheimer's disease: the epidemiological evidence CNS Neurol Disord Drug Targets 9 2010 132 139
62. E.E. Tuppo, and H.R. Arias The role of inflammation in Alzheimer's disease Int J Biochem Cell Biol 37 2005 289 305 (Pubitemid 39330191)
63. P. Eikelenboom, and W.A. van Gool Neuroinflammatory perspectives on the two faces of Alzheimer's disease J Neural Transm 111 2004 281 294 (Pubitemid 38316606)
64. M.T. Heneka, M.K. O'Banion, D. Terwel, and M.P. Kummer Neuroinflammatory processes in Alzheimer's disease J Neural Transm 117 2010 919 947
65. W.R. Markesbery, and J.M. Carney Oxidative alterations in Alzheimer's disease Brain Pathol 9 1999 133 146 (Pubitemid 29056524)
66. L. Munoz, and A.J. Ammit Targeting p38 MAPK pathway for the treatment of Alzheimer's disease Neuropharmacology 58 2010 561 568
67. S.A. Summers Ceramides in insulin resistance and lipotoxicity Prog Lipid Res 45 2006 42 72 (Pubitemid 43170804)
68. S.M. de la Monte Triangulated mal-signaling in Alzheimer's disease: roles of neurotoxic ceramides, ER stress, and insulin resistance reviewed J Alzheimers Dis 30 2012 S231 S249
69. S. Lee, M. Tong, S. Hang, C. Deochand, and S.M. de la Monte CSF and brain indices of insulin resistance, oxidative stress and neuro-inflammation in early versus late Alzheimer's disease J Alzheimers Dis Parkinsonism 3 2013 128
70. D. Galimberti, C. Fenoglio, and E. Scarpini Inflammation in neurodegenerative disorders: friend or foe Curr Aging Sci 1 2008 30 41
71. L. Olson, and C. Humpel Growth factors and cytokines/chemokines as surrogate biomarkers in cerebrospinal fluid and blood for diagnosing Alzheimer's disease and mild cognitive impairment Exp Gerontol 45 2010 41 46
72. V.P. Reddy, X. Zhu, G. Perry, and M.A. Smith Oxidative stress in diabetes and Alzheimer's disease J Alzheimers Dis 16 2009 763 774
73. J. Greilberger, D. Fuchs, F. Leblhuber, M. Greilberger, R. Wintersteiger, and E. Tafeit Carbonyl proteins as a clinical marker in Alzheimer's disease and its relation to tryptophan degradation and immune activation Clin Lab 56 2010 441 448
74. F. Gu, M. Zhu, J. Shi, Y. Hu, and Z. Zhao Enhanced oxidative stress is an early event during development of Alzheimer-like pathologies in presenilin conditional knock-out mice Neurosci Lett 440 2008 44 48
75. A. Gella, and N. Durany Oxidative stress in Alzheimer disease Cell Adhes Migrat 3 2009 88 93
76. A. Rahmadi, N. Steiner, and G. Munch Advanced glycation endproducts as gerontotoxins and biomarkers for carbonyl-based degenerative processes in Alzheimer's disease Clin Chem Lab Med 49 2011 385 391
77. M. Krautwald, and G. Munch Advanced glycation end products as biomarkers and gerontotoxins - a basis to explore methylglyoxal-lowering agents for Alzheimer's disease Exp Gerontol 45 2010 744 751
78. G.J. Chen, J. Xu, S.A. Lahousse, N.L. Caggiano, and S.M. de la Monte Transient hypoxia causes Alzheimer-type molecular and biochemical abnormalities in cortical neurons: potential strategies for neuroprotection J Alzheimers Dis 5 2003 209 228 (Pubitemid 37279552)
79. E. Tsukamoto, Y. Hashimoto, K. Kanekura, T. Niikura, S. Aiso, and I. Nishimoto Characterization of the toxic mechanism triggered by Alzheimer's amyloid-beta peptides via p75 neurotrophin receptor in neuronal hybrid cells J Neurosci Res 73 2003 627 636 (Pubitemid 37071748)
80. S.M. de la Monte, M. Tong, N. Lester-Coll, M. Plater Jr., and J.R. Wands Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer's disease J Alzheimers Dis 10 2006 89 109 (Pubitemid 44401370)
81. N. Kaplowitz, T.A. Than, M. Shinohara, and C. Ji Endoplasmic reticulum stress and liver injury Semin Liver Dis 27 2007 367 377 (Pubitemid 350071837)
82. H. Malhi, and G.J. Gores Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease Semin Liver Dis 28 2008 360 369
83. S. Sundar-Rajan, V. Srinivasan, M. Balasubramanyam, and U. Tatu Endoplasmic reticulum (ER) stress & diabetes Indian J Med Res 125 2007 411 424 (Pubitemid 46805455)
84. S.M. de la Monte, and M. Tong Mechanisms of nitrosamine-mediated neurodegeneration: potential relevance to sporadic Alzheimer's disease J Alzheimers Dis 17 2009 817 825
85. N. Kaplowitz, and C. Ji Unfolding new mechanisms of alcoholic liver disease in the endoplasmic reticulum J Gastroenterol Hepatol 21 Suppl 3 2006 S7 S9
86. B. Schisano, A.L. Harte, K. Lois, P. Saravanan, N. Al-Daghri, and O. Al-Attas et al. GLP-1 analogue, Liraglutide protects human umbilical vein endothelial cells against high glucose induced endoplasmic reticulum stress Regul Pept 174 2012 46 52
87. S. Hoyer Causes and consequences of disturbances of cerebral glucose metabolism in sporadic Alzheimer disease: therapeutic implications Adv Exp Med Biol 541 2004 135 152 (Pubitemid 38037371)
88. S. Chitturi, and G.C. Farrell Etiopathogenesis of nonalcoholic steatohepatitis Semin Liver Dis 21 2001 27 41 (Pubitemid 32240484)
89. G.J. Brewer Epigenetic oxidative redox shift (EORS) theory of aging unifies the free radical and insulin signaling theories Exp Gerontol 45 2010 173 179
90. D. Pessayre Role of mitochondria in non-alcoholic fatty liver disease J Gastroenterol Hepatol 22 Suppl 1 2007 S20 S27
91. E. Grunblatt, M. Salkovic-Petrisic, J. Osmanovic, P. Riederer, and S. Hoyer Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein J Neurochem 101 2007 757 770 (Pubitemid 46633313)
92. P. Kincaid-Smith Hypothesis: obesity and the insulin resistance syndrome play a major role in end-stage renal failure attributed to hypertension and labelled 'hypertensive nephrosclerosis' J Hypertens 22 2004 1051 1055 (Pubitemid 38720992)
93. H. Matsumoto, T. Nakao, T. Okada, Y. Nagaoka, H. Iwasawa, and R. Tomaru et al. Insulin resistance contributes to obesity-related proteinuria Intern Med 44 2005 548 553 (Pubitemid 40932826)
94. D. Etiene, J. Kraft, N. Ganju, T. Gomez-Isla, B. Gemelli, and B.T. Hyman et al. Cerebrovascular pathology contributes to the heterogeneity of Alzheimer's disease J Alzheimers Dis 1 1998 119 134
95. E.S. Korf, L.R. White, P. Scheltens, and L.J. Launer Brain aging in very old men with type 2 diabetes: the Honolulu-Asia aging study Diabetes Care 29 2006 2268 2274 (Pubitemid 44899864)
96. N. Sato, S. Takeda, K. Uchio-Yamada, H. Ueda, T. Fujisawa, and H. Rakugi et al. Role of insulin signaling in the interaction between Alzheimer disease and diabetes mellitus: a missing link to therapeutic potential Curr Aging Sci 4 2011 118 127
97. M. Holzenberger Igf-I signaling and effects on longevity Nestle Nutr Workshop Ser Pediatr Prog 68 2011 237 245 [discussion 46-9]
98. S. Valentini, F. Cabreiro, D. Ackerman, M.M. Alam, M.B. Kunze, and C.W. Kay et al. Manipulation of in vivo iron levels can alter resistance to oxidative stress without affecting ageing in the nematode C. elegans Mech Ageing Dev 133 2012 282 290
99. J. Zemva, M. Udelhoven, L. Moll, S. Freude, O. Stohr, and H.S. Bronneke et al. Neuronal overexpression of insulin receptor substrate 2 leads to increased fat mass, insulin resistance, and glucose intolerance during aging Age (Dordr) 35 2012 1881 1897
100. I. Castilla-Cortazar, M. Garcia-Fernandez, G. Delgado, J.E. Puche, I. Sierra, and R. Barhoum et al. Hepatoprotection and neuroprotection induced by low doses of IGF-II in aging rats J Transl Med 9 2011 103
101. R.M. Luque, Q. Lin, J. Cordoba-Chacon, P.V. Subbaiah, T. Buch, and A. Waisman et al. Metabolic impact of adult-onset, isolated, growth hormone deficiency (AOiGHD) due to destruction of pituitary somatotropes PloS One 6 2011 e15767
102. V. Srikanth, B. Westcott, J. Forbes, T.G. Phan, R. Beare, and A. Venn et al. Methylglyoxal, cognitive function and cerebral atrophy in older people J Gerontol A Biol Sci Med Sci 68 2012 68 73
103. R. Williamson, A. McNeilly, and C. Sutherland Insulin resistance in the brain: an old-age or new-age problem Biochem Pharmacol 84 2012 737 745
104. G. Oxenkrug Interferon-gamma - inducible inflammation: contribution to aging and aging-associated psychiatric disorders Aging Dis 2 2011 474 486
105. D. Horrillo, J. Sierra, C. Arribas, M. Garcia-San Frutos, J.M. Carrascosa, and N. Lauzurica et al. Age-associated development of inflammation in Wistar rats: effects of caloric restriction Arch Physiol Biochem 117 2011 140 150
106. D. Cai, and T. Liu Inflammatory cause of metabolic syndrome via brain stress and NF-kappaB Aging (Albany NY) 4 2012 98 115
107. D.J. Chiang, M.T. Pritchard, and L.E. Nagy Obesity, diabetes mellitus, and liver fibrosis Am J Physiol Gastrointest Liver Physiol 300 2011 G697 G702
108. G. Vernon, A. Baranova, and Z.M. Younossi Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults Aliment Pharmacol Ther 34 2011 274 285
109. S.M. de la Monte, A. Neusner, J. Chu, and M. Lawton Epidemiological trends strongly suggest exposures as etiologic agents in the pathogenesis of sporadic Alzheimer's disease, diabetes mellitus, and non-alcoholic steatohepatitis J Alzheimers Dis 17 2009 519 529
110. L.E. Lyn-Cook Jr., M. Lawton, M. Tong, E. Silbermann, L. Longato, and P. Jiao et al. Hepatic ceramide may mediate brain insulin resistance and neurodegeneration in type 2 diabetes and non-alcoholic steatohepatitis J Alzheimers Dis 16 2009 715 729
111. S.M. de la Monte, and J.R. Wands Alzheimer's disease is type 3 diabetes: evidence reviewed J Diabetes Sci Technol 2 2008 1101 1113
112. J. Capeau Insulin resistance and steatosis in humans Diabetes Metab 34 2008 649 657
113. E.W. Kraegen, and G.J. Cooney Free fatty acids and skeletal muscle insulin resistance Curr Opin Lipidol 19 2008 235 241 (Pubitemid 351653560)
114. J.A. Luchsinger, C. Reitz, B. Patel, M.X. Tang, J.J. Manly, and R. Mayeux Relation of diabetes to mild cognitive impairment Arch Neurol 64 2007 570 575 (Pubitemid 46588347)
115. S. Craft Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment Curr Alzheimer Res 4 2007 147 152 (Pubitemid 46557503)
116. K.L. Lokken, A.G. Boeka, H.M. Austin, J. Gunstad, and C.M. Harmon Evidence of executive dysfunction in extremely obese adolescents: a pilot study Surg Obes Relat Dis 5 2009 547 552
117. J. Gunstad, R.H. Paul, R.A. Cohen, D.F. Tate, M.B. Spitznagel, and E. Gordon Elevated body mass index is associated with executive dysfunction in otherwise healthy adults Compr Psychiatry 48 2007 57 61 (Pubitemid 44826976)
118. K. Yaffe Metabolic syndrome and cognitive decline Curr Alzheimer Res 4 2007 123 126 (Pubitemid 46557499)
119. G. Winocur, and C.E. Greenwood Studies of the effects of high fat diets on cognitive function in a rat model Neurobiol Aging 26 Suppl 1 2005 46 49
120. N. Moroz, M. Tong, L. Longato, H. Xu, and S.M. de la Monte Limited Alzheimer-type neurodegeneration in experimental obesity and Type 2 diabetes mellitus J Alzheimers Dis 15 2008 29 44
121. L.D. Baker, L.L. Frank, K. Foster-Schubert, P.S. Green, C.W. Wilkinson, and A. McTiernan et al. Aerobic exercise improves cognition for older adults with glucose intolerance, a risk factor for Alzheimer's disease J Alzheimers Dis 22 2010 569 579
122. L.D. Baker, L.L. Frank, K. Foster-Schubert, P.S. Green, C.W. Wilkinson, and A. McTiernan et al. Effects of aerobic exercise on mild cognitive impairment: a controlled trial Arch Neurol 67 2010 71 79
123. J. Bryan, and M. Tiggemann The effect of weight-loss dieting on cognitive performance and psychological well-being in overweight women Appetite 36 2001 147 156 (Pubitemid 32574227)
124. Y. Gu, J.A. Luchsinger, Y. Stern, and N. Scarmeas Mediterranean diet, inflammatory and metabolic biomarkers, and risk of Alzheimer's disease J Alzheimers Dis 22 2010 483 492
125. F. Pasquier, A. Boulogne, D. Leys, and P. Fontaine Diabetes mellitus and dementia Diabetes Metab 32 2006 403 414 (Pubitemid 44841847)
126. I.J. Martins, E. Hone, J.K. Foster, S.I. Sunram-Lea, A. Gnjec, and S.J. Fuller et al. Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease Mol Psychiatry 11 2006 721 736 (Pubitemid 44141805)
127. R.A. Whitmer Type 2 diabetes and risk of cognitive impairment and dementia Curr Neurol Neurosci Rep 7 2007 373 380 (Pubitemid 47422778)
128. P.T. Nelson, C.D. Smith, E.A. Abner, F.A. Schmitt, S.W. Scheff, and G.J. Davis et al. Human cerebral neuropathology of Type 2 diabetes mellitus Biochim Biophys Acta 1792 2009 454 469
129. J. Janson, T. Laedtke, J.E. Parisi, P. O'Brien, R.C. Petersen, and P.C. Butler Increased risk of type 2 diabetes in Alzheimer disease Diabetes 53 2004 474 481 (Pubitemid 38174565)
130. M. Tong, L. Longato, and S.M. de la Monte Early limited nitrosamine exposures exacerbate high fat diet-mediated type2 diabetes and neurodegeneration BMC Endocr Dis 10 2010 4
131. R.A. Whitmer, E.P. Gunderson, C.P. Quesenberry Jr., J. Zhou, and K. Yaffe Body mass index in midlife and risk of Alzheimer disease and vascular dementia Curr Alzheimer Res 4 2007 103 109 (Pubitemid 46557496)
132. W. Perry, R.C. Hilsabeck, and T.I. Hassanein Cognitive dysfunction in chronic hepatitis C: a review Dig Dis Sci 53 2008 307 321 (Pubitemid 351170036)
133. J.J. Weiss, and J.M. Gorman Psychiatric behavioral aspects of comanagement of hepatitis C virus and HIV Curr HIV/AIDS Rep 3 2006 176 181 (Pubitemid 44657376)
134. M. Tong, A. Neusner, L. Longato, M. Lawton, J.R. Wands, and S.M. de la Monte Nitrosamine exposure causes insulin resistance diseases: relevance to type 2 diabetes mellitus, non-alcoholic steatohepatitis, and Alzheimer's disease J Alzheimers Dis 17 2009 827 844
135. Y. Kao, J.H. Youson, J.A. Holmes, A. Al-Mahrouki, and M.A. Sheridan Effects of insulin on lipid metabolism of larvae and metamorphosing landlocked sea lamprey, Petromyzon marinus Gen Comp Endocrinol 114 1999 405 414 (Pubitemid 29256978)
136. W.L. Holland, and S.A. Summers Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism Endocr Rev 29 2008 381 402 (Pubitemid 351831506)
137. M. Langeveld, and J.M. Aerts Glycosphingolipids and insulin resistance Prog Lipid Res 48 2009 196 205
138. J.E. Elwing, P.J. Lustman, H.L. Wang, and R.E. Clouse Depression, anxiety, and nonalcoholic steatohepatitis Psychosom Med 68 2006 563 569 (Pubitemid 44297652)
139. V. Felipo, A. Urios, E. Montesinos, I. Molina, M.L. Garcia-Torres, and M. Civera et al. Contribution of hyperammonemia and inflammatory factors to cognitive impairment in minimal hepatic encephalopathy Metab Brain Dis 27 2011 51 58
140. K.S. Schmidt, J.L. Gallo, C. Ferri, T. Giovannetti, N. Sestito, and D.J. Libon et al. The neuropsychological profile of alcohol-related dementia suggests cortical and subcortical pathology Dement Geriatr Cogn Disord 20 2005 286 291 (Pubitemid 41442855)
141. M.D. Kopelman, A.D. Thomson, I. Guerrini, and E.J. Marshall The Korsakoff syndrome: clinical aspects, psychology and treatment Alcohol Alcohol 44 2009 148 154
142. S.M. de la Monte Triangulated mal-signaling in Alzheimer's disease: roles of neurotoxic ceramides, ER stress, and insulin resistance reviewed J Alzheimers Dis 30 2012 S231-S49
143. S.M. de la Monte, M. Tong, M. Lawton, and L. Longato Nitrosamine exposure exacerbates high fat diet-mediated type 2 diabetes mellitus, non-alcoholic steatohepatitis, and neurodegeneration with cognitive impairment Mol Neurodegener 4 2009 54
144. S.M. de la Monte, M. Tong, V. Nguyen, M. Setshedi, L. Longato, and J.R. Wands Ceramide-mediated insulin resistance and impairment of cognitive-motor functions J Alzheimers Dis 21 2010 967 984
145. M. Tong, and S.M. de la Monte Mechanisms of ceramide-mediated neurodegeneration J Alzheimers Dis 16 2009 705 714
146. A.V. Alessenko, A.E. Bugrova, and L.B. Dudnik Connection of lipid peroxide oxidation with the sphingomyelin pathway in the development of Alzheimer's disease Biochem Soc Trans 32 2004 144 146 (Pubitemid 38283036)
147. R.M. Adibhatla, and J.F. Hatcher Altered lipid metabolism in brain injury and disorders Subcell Biochem 49 2008 241 268
148. E. Kassi, P. Pervanidou, G. Kaltsas, and G. Chrousos Metabolic syndrome: definitions and controversies BMC Med 9 2011 48
149. Z.S. Tan, A.S. Beiser, C.S. Fox, R. Au, J.J. Himali, and S. Debette et al. Association of metabolic dysregulation with volumetric brain magnetic resonance imaging and cognitive markers of subclinical brain aging in middle-aged adults: the Framingham offspring study Diabetes Care 34 2011 1766 1770
150. S. Debette, A. Beiser, U. Hoffmann, C. Decarli, C.J. O'Donnell, and J.M. Massaro et al. Visceral fat is associated with lower brain volume in healthy middle-aged adults Ann Neurol 68 2010 136 144
151. J.J. Hassenstab, V. Sweat, H. Bruehl, and A. Convit Metabolic syndrome is associated with learning and recall impairment in middle age Dement Geriatr Cogn Disord 29 2010 356 362
152. V. Frisardi, V. Solfrizzi, C. Capurso, B.P. Imbimbo, G. Vendemiale, and D. Seripa et al. Is insulin resistant brain state a central feature of the metabolic-cognitive syndrome? J Alzheimers Dis 21 2010 57 63
153. K.F. Yates, V. Sweat, P.L. Yau, M.M. Turchiano, and A. Convit Impact of metabolic syndrome on cognition and brain: a selected review of the literature Arterioscler Thromb Vasc Biol 32 2012 2060 2067
154. J.M. Burns, R.A. Honea, E.D. Vidoni, L.J. Hutfles, W.M. Brooks, and R.H. Swerdlow Insulin is differentially related to cognitive decline and atrophy in Alzheimer's disease and aging Biochim Biophys Acta 1822 2012 333 339
155. J.A. Luchsinger Type 2 diabetes, related conditions, in relation and dementia: an opportunity for prevention? J Alzheimers Dis 20 2010 723 736
156. J.S. Delgado Evolving trends in nonalcoholic fatty liver disease Eur J Intern Med 19 2008 75 82
157. L.J. Launer Next steps in Alzheimer's disease research: interaction between epidemiology and basic science Curr Alzheimer Res 4 2007 141 143 (Pubitemid 46557501)
158. C. Nugent, and Z.M. Younossi Evaluation and management of obesity-related nonalcoholic fatty liver disease Nat Clin Pract Gastroenterol Hepatol 4 2007 432 441 (Pubitemid 47208893)
159. A. Pradhan Obesity, metabolic syndrome, and type 2 diabetes: inflammatory basis of glucose metabolic disorders Nutr Rev 65 2007 S152 S156
160. R.S. Rector, J.P. Thyfault, Y. Wei, and J.A. Ibdah Non-alcoholic fatty liver disease and the metabolic syndrome: an update World J Gastroenterol 14 2008 185 192 (Pubitemid 351314297)
161. P.F. Swann, and P.N. Magee Nitrosamine-induced carcinogenesis. The alklylation of nucleic acids of the rat by N-methyl-N-nitrosourea, dimethylnitrosamine, dimethyl sulphate and methyl methanesulphonate Biochem J 110 1968 39 47
162. L.B. Schook, J.F. Lockwood, S.D. Yang, and M.J. Myers Dimethylnitrosamine (DMN)-induced IL-1 beta, TNF-alpha, and IL-6 inflammatory cytokine expression Toxicol Appl Pharmacol 116 1992 110 116
163. G. Marchesini, and R. Marzocchi Metabolic syndrome and NASH Clin Liver Dis 11 2007 105 117 [ix] (Pubitemid 46829976)
164. M.R. Nicolls The clinical and biological relationship between Type II diabetes mellitus and Alzheimer's disease Curr Alzheimer Res 1 2004 47 54
165. D. Papandreou, I. Rousso, and I. Mavromichalis Update on non-alcoholic fatty liver disease in children Clin Nutr 26 2007 409 415 (Pubitemid 47091479)
166. Y. Wei, R.S. Rector, J.P. Thyfault, and J.A. Ibdah Nonalcoholic fatty liver disease and mitochondrial dysfunction World J Gastroenterol 14 2008 193 199 (Pubitemid 351314298)
167. M.M. Yeh, and E.M. Brunt Pathology of nonalcoholic fatty liver disease Am J Clin Pathol 128 2007 837 847 (Pubitemid 350133997)
168. K. Doi Studies on the mechanism of the diabetogenic activity of streptozotocin and on the ability of compounds to block the diabetogenic activity of streptozotocin (author's transl) Nippon Naibunpi Gakkai Zasshi 51 1975 129 147
169. T. Szkudelski The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas Physiol Res 50 2001 537 546 (Pubitemid 34087272)
170. S. Hoyer, H. Lannert, M. Noldner, and S.S. Chatterjee Damaged neuronal energy metabolism and behavior are improved by Ginkgo biloba extract (EGb 761) J Neural Transm 106 1999 1171 1188 (Pubitemid 30009214)
171. S. Iwai, T. Murai, S. Makino, W. Min, K. Morimura, and S. Mori et al. High sensitivity of fatty liver Shionogi (FLS) mice to diethylnitrosamine hepatocarcinogenesis: comparison to C3H and C57 mice Cancer Lett 246 2007 115 121 (Pubitemid 44959382)
172. A.A. Rossini, A.A. Like, W.L. Chick, M.C. Appel, and G.F. Cahill Jr. Studies of streptozotocin-induced insulitis and diabetes Proc Natl Acad Sci U S A 74 1977 2485 2489
173. M. Murata, A. Takahashi, I. Saito, and S. Kawanishi Site-specific DNA methylation and apoptosis: induction by diabetogenic streptozotocin Biochem Pharmacol 57 1999 881 887 (Pubitemid 29127100)
174. M. Nukatsuka, H. Sakurai, Y. Yoshimura, M. Nishida, and J. Kawada Enhancement by streptozotocin of O2-radical generation by the xanthine oxidase system of pancreatic beta-cells FEBS Lett 239 1988 295 298 (Pubitemid 18263464)
175. Z. Cai, Y. Zhao, S. Yao, and B. Bin Zhao Increases in beta-amyloid protein in the hippocampus caused by diabetic metabolic disorder are blocked by minocycline through inhibition of NF-kappaB pathway activation Pharmacol Rep 63 2011 381 391
176. S. Devaraj, P. Tobias, B.S. Kasinath, R. Ramsamooj, A. Afify, and I. Jialal Knockout of toll-like receptor-2 attenuates both the proinflammatory state of diabetes and incipient diabetic nephropathy Arterioscler Thromb Vasc Biol 31 2011 1796 1804
177. I.C. West Radicals and oxidative stress in diabetes Diabet Med 17 2000 171 180 (Pubitemid 30212288)
178. M. Labak, T. Foniok, D. Kirk, D. Rushforth, B. Tomanek, and A. Jasinski et al. Metabolic changes in rat brain following intracerebroventricular injections of streptozotocin: a model of sporadic Alzheimer's disease Acta Neurochir Suppl 106 2010 177 181
179. S. Wang, A. Kamat, P. Pergola, A. Swamy, F. Tio, and K. Cusi Metabolic factors in the development of hepatic steatosis and altered mitochondrial gene expression in vivo Metabolism 60 2011 1090 1099
180. S. Hoyer, D. Muller, and K. Plaschke Desensitization of brain insulin receptor. Effect on glucose/energy and related metabolism J Neural Transm Suppl 44 1994 259 268 (Pubitemid 24372903)
181. H. Lannert, and S. Hoyer Intracerebroventricular administration of streptozotocin causes long-term diminutions in learning and memory abilities and in cerebral energy metabolism in adult rats Behav Neurosci 112 1998 1199 1208 (Pubitemid 28519002)
182. F.H. Shi, Y. Wu, D.Z. Dai, X.D. Cong, Y.M. Zhang, and Y. Dai Hepatosteatosis and hepatic insulin resistance are blunted by argirein, an anti-inflammatory agent, through normalizing endoplasmic reticulum stress and apoptosis in diabetic liver J Pharm Pharmacol 65 2013 916 927
183. G.R. Gandhi, A. Stalin, K. Balakrishna, S. Ignacimuthu, M.G. Paulraj, and R. Vishal Insulin sensitization via partial agonism of PPARgamma and glucose uptake through translocation and activation of GLUT4 in PI3K/p-Akt signaling pathway by embelin in type 2 diabetic rats Biochim Biophys Acta 1830 2013 2243 2255
184. P. Moreno, B. Nuche-Berenguer, I. Gutierrez-Rojas, A. Acitores, V. Sancho, and I. Valverde et al. Normalizing action of exendin-4 and GLP-1 in the glucose metabolism of extrapancreatic tissues in insulin-resistant and type 2 diabetic states J Mol Endocrinol 48 2012 37 47
185. R. Duelli, H. Schrock, W. Kuschinsky, and S. Hoyer Intracerebroventricular injection of streptozotocin induces discrete local changes in cerebral glucose utilization in rats Int J Dev Neurosci 12 1994 737 743
186. L. Robbiano, E. Mereto, C. Corbu, and G. Brambilla DNA damage induced by seven N-nitroso compounds in primary cultures of human and rat kidney cells Mutat Res 368 1996 41 47 (Pubitemid 26156534)
187. J.K. Cataldo, J.J. Prochaska, and S.A. Glantz Cigarette smoking is a risk factor for Alzheimer's disease: an analysis controlling for tobacco industry affiliation J Alzheimers Dis 19 2010 465 480
188. P.B. Rosenberg Clinical aspects of inflammation in Alzheimer's disease Int Rev Psychiatry 17 2005 503 514 (Pubitemid 43086677)
189. M. Sastre, T. Klockgether, and M.T. Heneka Contribution of inflammatory processes to Alzheimer's disease: molecular mechanisms Int J Dev Neurosci 24 2006 167 176 (Pubitemid 43294623)
190. P. Katsel, C. Li, and V. Haroutunian Gene expression alterations in the sphingolipid metabolism pathways during progression of dementia and Alzheimer's disease: a shift toward ceramide accumulation at the earliest recognizable stages of Alzheimer's disease Neurochem Res 32 2007 845 856 (Pubitemid 46481322)
191. S.A. Summers Sphingolipids and insulin resistance: the five Ws Curr Opin Lipidol 21 2010 128 135
192. M.S. Han, S.Y. Park, K. Shinzawa, S. Kim, K.W. Chung, and J.H. Lee et al. Lysophosphatidylcholine as a death effector in the lipoapoptosis of hepatocytes J Lipid Res 49 2008 84 97
193. W.L. Holland, T.A. Knotts, J.A. Chavez, L.P. Wang, K.L. Hoehn, and S.A. Summers Lipid mediators of insulin resistance Nutr Rev 65 2007 S39 S46
194. C. Lipina, and H.S. Hundal Sphingolipids: agents provocateurs in the pathogenesis of insulin resistance Diabetologia 54 2011 1596 1607
195. R.A. DeFronzo Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009 Diabetologia 53 2010 1270 1287
196. K. Eckardt, A. Taube, and J. Eckel Obesity-associated insulin resistance in skeletal muscle: role of lipid accumulation and physical inactivity Rev Endocr Metab Dis 12 2011 163 172
197. L.A. Consitt, J.A. Bell, and J.A. Houmard Intramuscular lipid metabolism, insulin action, and obesity IUBMB Life 61 2009 47 55
198. C.P. Reynolds, B.J. Maurer, and R.N. Kolesnick Ceramide synthesis and metabolism as a target for cancer therapy Cancer Lett 206 2004 169 180 (Pubitemid 38317287)
199. J. Delarue, and C. Magnan Free fatty acids and insulin resistance Curr Opin Clin Nutr Metab Care 10 2007 142 148 (Pubitemid 46220305)
200. B. Liu, L.M. Obeid, and Y.A. Hannun Sphingomyelinases in cell regulation Semin Cell Dev Biol 8 1997 311 322 (Pubitemid 127346646)
201. W.N. Cong, R.Y. Tao, J.Y. Tian, G.T. Liu, and F. Ye The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice Life Sci 82 2008 983 990
202. M. Kolak, J. Westerbacka, V.R. Velagapudi, D. Wagsater, L. Yetukuri, and J. Makkonen et al. Adipose tissue inflammation and increased ceramide content characterize subjects with high liver fat content independent of obesity Diabetes 56 2007 1960 1968 (Pubitemid 47195815)
203. G. Arboleda, T.J. Huang, C. Waters, A. Verkhratsky, P. Fernyhough, and R.M. Gibson Insulin-like growth factor-1-dependent maintenance of neuronal metabolism through the phosphatidylinositol 3-kinase-Akt pathway is inhibited by C2-ceramide in CAD cells Eur J Neurosci 25 2007 3030 3038 (Pubitemid 46888810)
204. J.A. Chavez, W.L. Holland, J. Bar, K. Sandhoff, and S.A. Summers Acid ceramidase overexpression prevents the inhibitory effects of saturated fatty acids on insulin signaling J Biol Chem 280 2005 20148 20153 (Pubitemid 41379546)
205. C.E. Chalfant, K. Kishikawa, M.C. Mumby, C. Kamibayashi, A. Bielawska, and Y.A. Hannun Long chain ceramides activate protein phosphatase-1 and protein phosphatase-2A. Activation is stereospecific and regulated by phosphatidic acid J Biol Chem 274 1999 20313 20317
206. S.M. de la Monte, L. Lyn-Cook, M. Lawton, M. Tong, E. Silberman, and L. Longato et al. Hepatic ceramide may mediate brain insulin resistance and neurodegeneration in type 2 diabetes and non-alcoholic steatohepatitis Handbook of animal models in Alzheimer's disease vol. 1 2011 179 199
207. S.M. de la Monte Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease Curr Alzheimer Res 9 2012 35 66
208. L. Bryan, T. Kordula, S. Spiegel, and S. Milstien Regulation and functions of sphingosine kinases in the brain Biochim Biophys Acta 1781 2008 459 466